

# CV summary: Alberto Albanese, MD

Alberto Albanese graduated from the Catholic University Medical School in Rome, Italy, in 1977; he received his certification in Neurology in 1981 and in Psychiatry in 1985. From 1978 to 1979 Dr. Albanese was recipient of a Fulbright-Hays fellowship at the Brain Research Institute, University of California Los Angeles. In 1985-86 he was visiting professor at the Maudsley Hospital, London, with the late Professor David Marsden. In 1990 he received the Roussel prize for research on Ageing. In 1997 he was appointed Visiting professor at the University of Cordoba (Argentina) and in 2003 he was nominated *Membre d'honneur à titre étranger* by the French Neurological Society.

## Career

In 1984, Alberto Albanese was appointed Assistant Professor in Neurology and Director of the Movement Disorders clinic at the Gemelli hospital in Rome and in 1992 was appointed Associate Professor of Neurology. In 1996, he was appointed Professor of Neurology and co-Chairman of the Department of Neurology, University of Lausanne, Switzerland, where he stayed until 2000. In 2000, Alberto Albanese returned to his native country where he was appointed Professor of Neurology and Head Neurologist at the at the National Neurological Hospital "Carlo Besta", Milan. Since 2015 he is Head of the Department of Neurology at the Humanitas Research Hospital and University, Milan.

## Research interests

His first research interests were in basic science. Using morphological staining and tract-tracing techniques in the 1970s he studied the normal and abnormal activity of dopaminergic and cholinergic CNS neurons. He also evaluated animal models of disease developed using inbred mouse strains and monkeys rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

From the 1980s, Dr. Albanese became progressively more engaged in patient care and clinical research in the field of movement disorders and was a fellow in London with the late David Marsden, first in Denmark Hill and then in Queen Square. His research interest became focused mainly on dystonia, Parkinson's disease, and other parkinsonian syndromes (such as multiple system atrophy). His publications cover an ample spectrum of movement disorders, including Parkinson disease, dystonia, choreas and tics. He has been a pioneer in the introduction of botulinum toxins in Italy and has pioneered the use of deep brain stimulation in Parkinson's disease and other movement disorders. In this clinical capacity, Prof. Albanese has raised several generations of Italian neurologists with expertise in movement disorders and has mentored medical graduates who now hold neurological positions of international stance.

Aside his administrative tasks of department Chair at Humanitas, Prof. Albanese is charged of developing excellence in research and clinical care for neurological degenerative diseases.

## Scientific activity

Alberto Albanese has published over 400 publications, including more than 350 scientific papers on indexed journals and several chapters on multi-authored books. His H index is 69, has coordinated nation-wide scientific projects in Italy and Switzerland and has received grants from a number of Italian and international granting agencies. He is Editor in Chief of *Frontiers in Movement Disorders*, Associate Editor of the *European Journal of Neurology* since 2007 and of *Therapeutic Advances in Neurological Disorders* from 2008 to 2010. Has been on the editorial board of *Movement Disorders* and of *European Neurology* from 1996 to 2000 and currently is in the editorial board of *Current Neuropharmacology*. He has been member

of the *Faculty of 1000*, and has peer reviewed for a number of neurological journals, including: *Brain*, *Brain Dysfunction*, *Brain Research Bulletin*, *Electroencephalography and clinical neurophysiology*, *European Journal of Neurology*, *European Neurology*, *Fundamental & Clinical Pharmacology*, *Journal of Neurology*, *Lancet*, *Nature*, *Journal of Neurology Neurosurgery and Psychiatry*, *Movement Disorders*, *Neurology*, *Neurological Sciences*, *Neuroscience Letters*, *New England Journal of Medicine*.

Prof. Albanese has chaired the [International Conference on Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins](#) (Baveno, Italy, 2008), and has been member of the organizing committee of several international congresses, including the [8<sup>th</sup> Movement Disorders Society Congress](#) (Rome, 2004), the [Nineteenth Meeting of the European Neurological Society](#) (Milan, 2008) and the [XVIII WFN World Congress on Parkinson's Disease and Other Movement Disorders](#) (Miami Beach, 2009). He is currently Chair of the Scientific Committee of Toxins 2017: Basic Science and Clinical Aspects of Botulinum and Other Neurotoxins (Madrid, 2017).

Prof. Albanese has been President of the *International Neurotoxin Association* and is an honorary member of the French Neurological Society and of the Swiss Neurological Society. He is regular member of the following scientific societies: the Italian Neurological Society (since 1980; repeatedly and currently member of the executive committee), the Italian Movement Disorders Society (founder, President 2006-2007, currently member of the executive committee), the Movement Disorders Society (previously member of the Education Committee, currently Chair of the Study Group on Dystonia), the American Academy of Neurology (corresponding Fellow since 1991) and the European Academy of Neurology (Fellow of the EAN).

### Research identity

Scopus ID: 7101798303

ORCID ID: 0000-0002-5864-0006

ResearcherID: K-7396-2016



### Bibliometric indexes <sup>1</sup>

Hirsch index	69
Total citations	21'526
Published papers	363

### Mailing address

Prof. Alberto Albanese

Istituto Clinico Humanitas

Via A. Manzoni, 56

I-20089 Rozzano Milano (Italy)

Telephone +39 (02) 8224-6418

Facsimile +39 (02) 8224-2298

e-Mail [alberto.albanese@unicatt.it](mailto:alberto.albanese@unicatt.it), [alberto.albanese@humanitas.it](mailto:alberto.albanese@humanitas.it)

---

<sup>1</sup> Source: Scopus, April 2021.